Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
复制标题
在具有EGFR激活突变和脑转移的NSCLC患者中，与单独的Osimertinib相比，osimertinib加颅放疗的治疗作用：一项回顾性研究。
DOI：
10.1186/s13014-021-01955-7
复制
发表时间：
2021-12-05
期刊：
影响因子：
--
通讯作者：
Yu J
中科院分区：
文献类型：
--
作者：
Zhai X;Li W;Li J;Jia W;Jing W;Tian Y;Xu S;Li Y;Zhu H;Yu J
The study aimed to compare the efficacy of osimertinib plus cranial radiotherapy (RT) with osimertinib alone in advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations and brain metastases (BMs). The clinical data of advanced NSCLC patients with BMs who received osimertinib were retrospectively collected. The patients were assigned to one of the two groups according to the therapeutic modality used: the osimertinib monotherapy group or the osimertinib plus RT group. This was a retrospective study and 61 patients were included from December 2015 to August 2020. Forty patients received osimertinib monotherapy, and twenty-one patients received osimertinib plus RT. Radiotherapy included whole-brain radiation therapy (WBRT, n = 14), WBRT with simultaneous integrated boost (WBRT-SIB, n = 5) and stereotactic radiosurgery (SRS, n = 2). The median number of prior systemic therapies in the two groups was one. Intracranial and systemic ORR and DCR were not significantly different between the two groups. No difference in iPFS was observed between the two groups (median iPFS: 16.67 vs. 13.50 months, P = 0.836). The median OS was 29.20 months in the osimertinib plus RT group compared with 26.13 months in the osimertinib group (HR = 0.895, P = 0.826). In the L858R mutational subgroup of 31 patients, the osimertinib plus RT group had a longer OS (P = 0.046). In the exon 19 deletion mutational subgroup of 30 patients, OS in the osimertinib alone group was longer than that in the osimertinib plus RT group (P = 0.011). The incidence of any-grade adverse events was not significantly different between the osimertinib plus RT group and the osimertinib alone group (47.6% vs. 32.5%, P = 0.762). However, six patients (28.5%) experienced leukoencephalopathy in the osimertinib plus RT group, and 50% (3/6) of the leukoencephalopathy was greater than or equal to grade 3. The therapeutic effect of osimertinib with RT was similar to that of osimertinib alone in EGFR-positive NSCLC patients with BM. However, for patients with the L858R mutation, osimertinib plus RT could provide more benefit than osimertinib alone.
登录
查看更多内容
影响因子：
5.8
作者：
Xie, Lijia;Nagpal, Seema;Neal, Joel W.
通讯作者：
Neal, Joel W.
DOI：
10.1007/s00432-018-2781-7
发表时间：
2019-01-01
影响因子：
3.6
作者：
Alongi, Filippo;Fiorentino, Alba;Ruggieri, Ruggero
通讯作者：
Ruggieri, Ruggero
对于 NSCLC 和 EGFR 突变和脑转移患者，EGFR TKI 联合 WBRT 与单独使用 TKI 相比没有任何生存获益
影响因子：
20.4
作者：
Jiang, Tao;Su, Chunxia;Zhang, Jun
通讯作者：
Zhang, Jun
影响因子：
158.5
作者：
Soria, J. -C.;Ohe, Y.;Nguyen, Nhung
通讯作者：
Nguyen, Nhung
影响因子：
45.3
作者：
Yang, James C. H.;Kim, Sang-We;Ahn, Myung-Ju
通讯作者：
Ahn, Myung-Ju